Rising Pharma Recalls 4 Cetirizine Lots Over Ranitidine Contamination Risk
Updated
Updated · WSB Atlanta · Jul 21
Rising Pharma Recalls 4 Cetirizine Lots Over Ranitidine Contamination Risk
3 articles · Updated · WSB Atlanta · Jul 21
Summary
Four lots of 5-mg cetirizine hydrochloride tablets in 100-count bottles were recalled July 18 after possible cross-contamination with ranitidine, an FDA notice said.
A pharmacy technician spotted a red dot on some tablets, prompting manufacturer Unique Pharmaceutical Laboratories to alert distributor Rising Pharma, which then notified distributors and customers by email.
Nationwide bottles can be identified by NDC 16571-401-10, expiration 10/2028 and lot numbers GY825029, GY825030, GY825031 and GY825032.
No adverse reactions have been reported, but patients sensitive to ranitidine could face anaphylaxis, including trouble swallowing, shortness of breath, low blood pressure or loss of consciousness.
Consumers are urged to contact physicians over possible symptoms and report problems to FDA MedWatch; Rising Pharma has not said how many bottles were affected.